As of 2026-03-26, the EV/EBITDA ratio of Medipharm Labs Corp (LABS.TO) is -2.14. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LABS.TO's latest enterprise value is 17.45 mil CAD. LABS.TO's TTM EBITDA according to its financial statements is -8.17 mil CAD. Dividing these 2 quantities gives us the above LABS.TO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 16.7x - 19.1x | 17.9x |
| Forward P/E multiples | 11.5x - 19.3x | 15.4x |
| Fair Price | (0.30) - (0.34) | (0.30) |
| Upside | -557.4% - -628.4% | -555.9% |
| Date | EV/EBITDA |
| 2026-03-20 | -2.14 |
| 2026-03-19 | -2.14 |
| 2026-03-18 | -2.14 |
| 2026-03-17 | -2.14 |
| 2026-03-16 | -2.14 |
| 2026-03-13 | -2.14 |
| 2026-03-12 | -2.14 |
| 2026-03-11 | -2.14 |
| 2026-03-10 | -2.40 |
| 2026-03-09 | -2.40 |
| 2026-03-06 | -2.14 |
| 2026-03-05 | -2.40 |
| 2026-03-04 | -2.40 |
| 2026-03-03 | -2.66 |
| 2026-03-02 | -2.66 |
| 2026-02-27 | -2.40 |
| 2026-02-26 | -2.40 |
| 2026-02-25 | -2.66 |
| 2026-02-24 | -2.14 |
| 2026-02-23 | -2.40 |
| 2026-02-20 | -2.14 |
| 2026-02-19 | -2.14 |
| 2026-02-18 | -2.14 |
| 2026-02-17 | -2.14 |
| 2026-02-13 | -2.40 |
| 2026-02-12 | -2.14 |
| 2026-02-11 | -2.14 |
| 2026-02-10 | -2.14 |
| 2026-02-09 | -2.14 |
| 2026-02-06 | -2.40 |
| 2026-02-05 | -2.40 |
| 2026-02-04 | -2.40 |
| 2026-02-03 | -2.40 |
| 2026-02-02 | -2.40 |
| 2026-01-30 | -2.14 |
| 2026-01-29 | -2.40 |
| 2026-01-28 | -2.40 |
| 2026-01-27 | -2.40 |
| 2026-01-26 | -2.40 |
| 2026-01-23 | -2.40 |
| 2026-01-22 | -2.40 |
| 2026-01-21 | -2.40 |
| 2026-01-20 | -2.40 |
| 2026-01-19 | -2.40 |
| 2026-01-16 | -2.66 |
| 2026-01-15 | -2.66 |
| 2026-01-14 | -2.40 |
| 2026-01-13 | -2.40 |
| 2026-01-12 | -2.66 |
| 2026-01-09 | -2.40 |